Youngji Jo

Youngji Jo

Auto-generated profile, based on publicly available information

Youngji Jo

Departments of Public Health Sciences, School of Medicine, UConn Health, Farmington, CT, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2019 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
YJYoungji Jo
Youngji Jo
KAKelsey Alland
Kelsey Alland
HAHasmot Ali
Hasmot Ali
SMSucheta Mehra
Sucheta Mehra
ALAmnesty E. LeFevre
Amnesty E. LeFevre
ALAlain B. Labrique
Alain B. Labrique
Background: Measurement of antenatal care (ANC) service coverage is often limited to the number of contacts or type of providers, reflecting a gap in the assessment of quality as well as cost estimations and health impact. The study aims to determine service subcomponents and provider and patient costs of ANC services and compares them between community (i.e. satellite clinics) and facility care (i.e. primary and secondary health centers) settings in rural Bangladesh. Methods: Service contents and cost data were collected by one researcher and four interviewers in various community and facility health care settings in Gaibandha district between September and December 2016. We conducted structured interviews with organization managers, observational studies of ANC service provision (n = 70) for service contents and provider costs (service and drug costs) and exit interviews with pregnant women (n = 70) for patient costs (direct and indirect costs) in health clinics at community and facility levels. Fisher’s exact tests were used to determine any different patient characteristics between community and facility settings. ANC service contents were assessed by 63 subitems categorized into 11 groups and compared within and across community and facility settings. Provider and patient costs were collected in Bangladesh taka and analyzed as 2016 US Dollars (0.013 exchange rate). Results: We found generally similar provider and patient characteristics between the community and facility settings except in clients’ gestational age. High compliance (> 50%) of service subcomponents were observed in blood pressure monitoring, weight measurement, iron and folate supplementation given, and tetanus vaccine, while lower compliance of service subcomponents (< 50%) were observed in some physical examinations such as edema and ultrasonogram and routine tests such as blood test and urine test. Average unit costs of ANC service provision were about double at the facility level ($2.75) compared with community-based care ($1.62). ANC patient costs at facilities ($2.66) were about three times higher than in the community ($0.78). Conclusion: The study reveals a delay in pregnant women’s initial ANC care seeking, gaps in compliance of ANC subcomponents and difference of provider and patient costs between facility and community settings.

12 March 2022 in Epidemiology and Health
Verified
Journal Article
Open access
PDF file
YJYoungji Jo
Youngji Jo
SKSun Bean Kim
Sun Bean Kim
MRMunkhzul Radnaabaatar
Munkhzul Radnaabaatar
KHKyungmin Huh
Kyungmin Huh
JYJin-Hong Yoo
Jin-Hong Yoo
JJJaehun Jung
Jaehun Jung
OBJECTIVES: Many countries have authorized the emergency use of oral antiviral agents for patients with mild-to-moderate cases of coronavirus disease 2019 (COVID-19). We assessed the cost-effectiveness of these agents for reducing the number of severe COVID-19 cases and the burden on Korea’s medical system.METHODS: Using an existing model, we estimated the number of people who would require hospital/intensive care unit (ICU) admission in Korea in 2022. The treatment scenarios included (1) all adult patients, (2) elderly patients only, and (3) adult patients with underlying diseases only, compared to standard care. Based on the current health system capacity, we calculated the incremental costs per severe case averted and hospital admission for each scenario.RESULTS: We estimated that 236,510 COVID-19 patients would require hospital/ICU admission in 2022 with standard care only. Nirmatrelvir/ritonavir (87% efficacy) was predicted to reduce this number by 80%, 24%, and 17% when targeting all adults, adults with underlying diseases, and elderly patients (25, 8, and 4%, respectively, for molnupiravir, with 30% efficacy). Nirmatrelvir/ritonavir use is likely to be cost-effective, with predicted costs of US$8,878, US$8,964, and US$1,454, per severe patient averted for the target groups listed above, respectively, while molnupiravir is likely to be less cost-effective, with costs of US$28,492, US$29,575, and US$7,915, respectively.CONCLUSIONS: In Korea, oral treatment using nirmatrelvir/ritonavir for symptomatic COVID-19 patients targeting elderly patients would be highly cost-effective and would substantially reduce the demand for hospital admission to below the capacity of the health system if targeted to all adult patients instead of standard care.

29 January 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
YJYoungji Jo
Youngji Jo
LJLise Jamieson
Lise Jamieson
IEIjeoma Edoka
Ijeoma Edoka
LLLawrence Long
Lawrence Long
SSSheetal Silal
Sheetal Silal
BNBrooke Nichols
Brooke Nichols
Background: Dexamethasone and remdesivir have the potential to reduce coronavirus disease 2019 (COVID)–related mortality or recovery time, but their cost-effectiveness in countries with limited intensive care resources is unknown.Methods: We projected intensive care unit (ICU) needs and capacity from August 2020 to January 2021 using the South African National COVID-19 Epi Model. We assessed the cost-effectiveness of (1) administration of dexamethasone to ventilated patients and remdesivir to nonventilated patients, (2) dexamethasone alone to both nonventilated and ventilated patients, (3) remdesivir to nonventilated patients only, and (4) dexamethasone to ventilated patients only, all relative to a scenario of standard care. We estimated costs from the health care system perspective in 2020 US dollars, deaths averted, and the incremental cost-effectiveness ratios of each scenario.Results: Remdesivir for nonventilated patients and dexamethasone for ventilated patients was estimated to result in 408 (uncertainty range, 229–1891) deaths averted (assuming no efficacy [uncertainty range, 0%–70%] of remdesivir) compared with standard care and to save $15 million. This result was driven by the efficacy of dexamethasone and the reduction of ICU-time required for patients treated with remdesivir. The scenario of dexamethasone alone for nonventilated and ventilated patients requires an additional $159 000 and averts 689 [uncertainty range, 330–1118] deaths, resulting in $231 per death averted, relative to standard care.Conclusions: The use of remdesivir for nonventilated patients and dexamethasone for ventilated patients is likely to be cost-saving compared with standard care by reducing ICU days. Further efforts to improve recovery time with remdesivir and dexamethasone in ICUs could save lives and costs in South Africa.

9 September 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YJYoungji Jo
Youngji Jo
MKMary Kagujje
Mary Kagujje
KJKarl Johnson
Karl Johnson
DDDavid Dowdy
David Dowdy
PHPeter Hangoma
Peter Hangoma
HSHojoon Sohn
Hojoon Sohn
Introduction: Active-case finding (ACF) programs have an important role in addressing case detection gaps and halting tuberculosis (TB) transmission. Evidence is limited on the cost-effectiveness of ACF interventions, particularly on how their value is impacted by different operational, epidemiological and patient care-seeking patterns. Methods: We evaluated the costs and cost-effectiveness of a combined facility and community-based ACF intervention in Zambia that utilized mobile chest X-ray with computer-aided reading/interpretation software and laboratory-based Xpert MTB/RIF testing. Programmatic costs (in 2018 US dollars) were assessed from the health system perspective using prospectively collected cost and operational data. Cost-effectiveness of the ACF intervention was assessed as the incremental cost per TB death averted over a five-year time horizon using a multi-stage Markov state-transition model reflecting patient symptom-associated care-seeking and TB care under ACF compared to passive care. Results: Over 18 months of field operations, the ACF intervention costed $435 to diagnose and initiate treatment for one person with TB. After accounting for patient symptom-associated care-seeking patterns in Zambia, we estimate that this one-time ACF intervention would incrementally diagnose 407 (7,207 versus 6,800) TB patients and avert 502 (611 versus 1,113) TB-associated deaths compared to the status quo (passive case finding), at an incremental cost of $2,284 per death averted over the next five-year period. HIV/TB mortality rate, patient symptom-associated care-seeking probabilities in the absence of ACF, and the costs of ACF patient screening were key drivers of cost-effectiveness. Conclusions: A one-time comprehensive ACF intervention simultaneously operating in public health clinics and corresponding catchment communities can have important medium-term impact on case-finding and be cost-effective in Zambia. The value of such interventions increases if targeted to populations with high HIV/TB mortality, substantial barriers (both behavioral and physical) to care-seeking exist, and when ACF interventions can optimize screening by achieving operational efficiency.

2 November 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
YJYoungji Jo
Youngji Jo
SSSourya Shrestha
Sourya Shrestha
IGIsabella Gomes
Isabella Gomes
SMSuzanne Marks
Suzanne Marks
AHAndrew Hill
Andrew Hill
DDDavid Dowdy
David Dowdy
Background: Targeted testing and treatment (TTT) for latent tuberculosis (TB) infection (LTBI) is a recommended strategy to accelerate TB reductions and further TB elimination in the United States. Evidence on cost-effectiveness of TTT for key populations can help advance this goal. Methods: We used a model of TB transmission to estimate the numbers of individuals who could be tested by interferon-γ release assay and treated for LTBI with 3 months of self-administered rifapentine and isoniazid (3HP) under various TTT scenarios. Specifically, we considered rapidly scaling up TTT among people who are non–US-born, diabetic, living with human immunodeficiency virus (HIV), homeless or incarcerated in California, Florida, New York, and Texas—states where more than half of US TB cases occur. We projected costs (from the healthcare system perspective, in 2018 dollars), 30-year reductions in TB incidence, and incremental cost-effectiveness (cost per quality-adjusted life-year [QALY] gained) for TTT in each modeled population. Results: The projected cost-effectiveness of TTT differed substantially by state and population, while the health impact (number of TB cases averted) was consistently greatest among non–US-born individuals. TTT was most cost-effective among persons with HIV (from $2828/QALY gained in Florida to $11 265/QALY gained in New York) and least cost-effective among people with diabetes (from $223 041/QALY gained in California to $817 753/QALY in New York). Conclusions: The modeled cost-effectiveness of TTT for LTBI varies across states but was consistently greatest among people with HIV; moderate among people who are non–US-born, incarcerated, or homeless; and least cost-effective among people with diabetes.

27 July 2018 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
ALAmnesty LeFevre
Amnesty LeFevre
MCMaria A Cabrera-Escobar
Maria A Cabrera-Escobar
DMDiwakar Mohan
Diwakar Mohan
JEJaran Eriksen
Jaran Eriksen
DRDebbie Rogers
Debbie Rogers
JCJesse Coleman
Jesse Coleman
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Limited evidence exists on the value for money of SMS health information programs in low resource settings. Objective: Drawing from data collected as part of a retrospective study exploring the effectiveness of messaging exposure on utilization of maternal and child health services, we modelled the incremental cost effectiveness of gradually scaling up messaging services to pregnant women throughout Gauteng province, South Africa from 2012-2017. Methods: Stage based maternal health SMSs were sent to pregnant women twice per week in pregnancy and continued until the infant's first birthday. Program costs, incremental costs to users and the health system, were measured along with changes in utilization of antenatal care (ANC) visits and childhood immunizations, and compared against a control group of pregnant women who received no SMS messages. Incremental changes in utilization were inputted into the Lives Saved Tool and used to forecast lives saved and DALYs averted of gradually scaling up program activities to reach 60% of pregnant women across Gauteng province within 5 years. Uncertainty was characterized using one way and probabilistic uncertainty analyses. Results: Five-year program costs are estimated to be $1.2 million USD; 17% of which were incurred by costs on program development and 31% on SMS message delivery costs. Costs to users were $1.66 to attend clinic based services; nearly 90% of which was attributed to wages lost. Costs to the health system included provider time costs to register MAMA users ($0.08) and provide ANC 1-4 ($4.36) and PNC 1-5 ($3.08) services. Incremental costs per DALY averted from a societal perspective ranged from $1,985 USD in the first year of implementation to $200 USD in the 5th year. At a willingness to pay threshold of $2,000 USD, the project had a 40% probability of being cost effective in year 1 versus 100% in all years thereafter. Conclusions: Study findings suggest that SMS health information messages delivered to pregnant women may be a cost-effective strategy for bolstering ANC and childhood immunizations, even at very small margins of coverage increases. Primary data obtained prospectively as part of more rigorous study designs are needed to validate modelled results. Clinical Trial: Not applicable